Tardive dyskinesia and essential fatty acids

International Review of Psychiatry

Volumn 18, Issue 2, 2006, Pages 133-143

  Vaddadi, Krishna ^a   Hakansson, Kerstin ^b,c   Clifford, Jerry ^c,d   Waddington, John ^c  

^a MONASH MEDICAL CENTRE   (Australia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d Munster Technological University   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIOXIDANT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIHOMO GAMMA LINOLENIC ACID; DIPHENYLDISELENIDE; DOCOSAHEXAENOIC ACID; DOPAMINE RECEPTOR BLOCKING AGENT; EBSELEN; ESSENTIAL FATTY ACID; GAMMA LINOLENIC ACID; HALOPERIDOL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; MELATONIN; MOOD STABILIZER; NEUROLEPTIC AGENT; NICOTINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PRIMROSE OIL; PROSTAGLANDIN; PSYCHOTROPIC AGENT; QUERCETIN; TACROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGING; BALANCE DISORDER; CELL FUNCTION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; ERYTHROCYTE; HEREDITY; HUMAN; LONG TERM CARE; NERVE CELL; NERVE CELL MEMBRANE; NEUROLOGIC DISEASE; NIGRONEOSTRIATAL SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FATTY ACIDS, ESSENTIAL; HUMANS; RECEPTORS, CHOLINERGIC; RECEPTORS, DOPAMINE; RISK FACTORS; SUBSTANTIA NIGRA;

EID: 33646921816     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260600583114     Document Type: Review

References (163)

1. Abilio, V. C., Araujo, C. C., Bergamo, M., Calvente, P. R., D'Almeida, V., Ribeiro Rdem, A., et al. (2003). Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats. Progress in Neuropsychopharmacology & Biological Psychiatry, 27(1), 109-114.
2. Abilio, V. C., Silva, R. H., Carvalho, R. C., Grassl, C., Calzavara, M. B., Registro, S., et al. (2004). Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology, 47(2), 263-272.
3. American Psychiatric Association (2000). Diagnostic & Statistical Manual of Mental Disorders-IV- TR (4th ed.). Washington DC: American Psychiatric Association.
4. Anderson, J. J., Kask, A. M., & Chase, T. N. (1996). Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. European Journal of Pharmacology, 295(2-3), 163-168.
5. Andreassen, O. A., & Jorgensen, H. A. (2000). Neurotoxicity associated with neuroleptic-induced oral dyskinesia in rats; implications for tardive dyskinesia. Progress in Neurobiology, 61, 525-541.
6. Arvindakshan, M., Ghate, M., Ranjekar, P. K., Evans, D. R., & Mahadik, S. P. (2003). Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research, 62, 195-204.
7. Assies, J., Lieverse, R., Vreken, P., Wanders, R. J., Dingemans, P. M., & Linszen, D. H. (2001). Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biological Psychiatry, 49(6), 510-522.
8. Barnes, T. R., Liddle, P.F, Curson, D. A., & Patel, M. (1989). Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia. British Journal of Psychiatry, 7, 99-103.
9. Basavarajappa, B. S., & Hungund, B. L. (2002). Neuromodulatory role of the endocannabinoid signaling system in alcoholism: An overview. Prostaglandins Leukotrienes Essential Fatty Acids, 66, 287-299.
10. Berger, A., Crozier, G., Bisogno, T., Cavaliere, P., Innis, S., & Di Marzo, V. (2001). Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proceedings of the National Academy of Science of the USA, 98(11), 6402-6406.
11. Brenner, R. R. (1971). The desaturation step in the animal biosynthesis of polyunsaturated fatty acids. Lipids, 6(8), 567-575.
12. Burger, M., Fachinetto, R., Calegari, L., Paixao, M. W., Braga, A. L., & Rocha, J. B. (2004). Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide. Brain Research Bulletin, 64(4), 339-345.
13. Burger, M. E., Alves, A., Callegari, L., Athayde, F. R., Nogueira, C. W., Zeni, G., et al. (2003). Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Progress in Neuropsychopharmacology & Biological Psychiatry, 27(1), 135-140.
14. Burger, M. E., Fachineto, R., Alves, A., Callegri, L., & Rocha, J. B. (2005). Acute reserpine and subchronic haloperidol treatment change synaptosomal brain glutamate uptake and elicit oroacial dyskinesia in rats. Brain Research, 1031(2), 202-210.
15. Cadet, J. L., & Lohr, J. B. (1989). Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Annals of the New York Acadademy of Sciences, 570, 176-185.
16. Caligiuri, M. P., & Jeste, D. V. (2004). Association of diabetes with dyskinesia in older psychosis patients. Psychopharmacology (Berlin), 176, 281-286.
17. Carlson, S. E., Carver, J. D., & House, S. G. (1986). High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: A comparison of rat neural and red cell membrane phospholipids. The Journal of Nutrition, 116(5), 718-725.
18. Casey, D. E. (1985). Tardive dyskinesia: Non-dopaminergic treatment approaches. Psychopharmacology, 2, 137-144.
19. Casey, D. E. (2004). Pathophysiology of antipsychotic drug-induved movement disorders. Journal of Clinical Psychology, 65(9), 25-28.
20. Castilho, R. F., Hansson, O., & Brundin, P. (2000). Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Progress in Brain Research, 127, 203-231.
21. Chong, S. A., Tan, E. C., Tan, C. H., Mythily, S., & Chan, Y. H. (2003). Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 116(1), 51-54.
22. Chouinard, G., Annable, L., Ross-Chouinard, A., & Mercier, P. (1988). A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. Journal of Clinical Psychopharmacology, 8(4), 21S-26S.
23. Clifford, J. J., Drago, J., Natoli, A. L., Wong, J. Y., Kinsella, A., Waddington, J. L., et al. (2002). Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience, 109(1), 81-88.
24. Connor, W. E., DeFrancesco, C. A., & Connor, S. L. (1993). N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Annals of the New York Academy of Sciences, 683, 16-34.
25. Correll, C. U., Leucht, S., & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry, 161(3), 414-425.
26. Costall, B., Kelly, M. E., & Naylor, R. J. (1984). The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent. British Journal of Pharmacology, 83(3), 733-740.
27. Coyle, J. T., & Puttfarcken, P. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science, 262(5134), 689-695.
28. Csernansky, J. G., Kaplan, J., Holman, C. A., & Hollister, L. E. (1983). Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berl), 81(2), 115-118.
29. Cunningham Owens, D. G. (1999). Tardive dyskinesia. In D. G. Cunningham Owens (Ed.), A Guide to the Extrapyramidal Side-Effects of Antipsychotic drugs (pp. 166-226). Cambridge: University Press.
30. de Leon, J., Susce, M. T., Pan, R. M., Koch, W. H., & Wedlund, P. J. (2005). Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. Journal of Clinical Psychopharmacology, 25, 448-456.
31. D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558-1572.
32. Das, U. N., & Vaddadi, K. S. (2004). Essential fatty acids in Huntington disease. Nutrition, 20(10), 942-947.
33. Delfs, J. M., Ciaramitaro, V. M., Soghomonian, J. J., & Chesselet, M. F. (1996). Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarbocylase messenger RNA in the reticular thalamic nucleus. Neuroscience, 71(2), 383-395.
34. Deshpande, S. N., Varma, P. G., Semwal, P., Rao, A. R., Bhhatia, T., Nimgaonkar, V. L., et al. (2005). Serotonin receptor gene polymorphism and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatric Genetics, 15(3), 157-158.
35. Dixon, L., Weiden, P. J., Haas, G., Sweeney, J., & Frances, A. J. (1992). Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comprehensive Psychiatry, 33(2), 121-122.
36. Ellingrod, V. L., Schultz, S. K., & Arndt, S. (2002). Abnormal movements and tardive dyskinesia in smokers and non-smokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy, 22(11), 1416-1419.
37. Evans, D. R., Parikh, V. V., Khan, M. M., Coussons, C., Buckley, P. F., & Mahadik, S. P. (2003). Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, 69(6), 393-399.
38. Fenton, W. S., Hibbeln, J., & Knable, M. (2000). Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry, 47(1), 8-21.
39. Gattaz, W. F., Emrich, A., & Behrens, S. (1993). Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: Possible implications for tardive dyskinesia. Journal of Neural Transmission. General Section, 92(2-3), 197-201.
40. Gattaz, W. F., Hubner, C. V., Nevalainen, T. J., Thuren, T., & Kinnunen, P. K. (1990). Increased serum phospholipase A2 activity in schizophrenia: A replication study. Biological Psychiatry, 28(6), 495-501.
41. Gattaz, W. F., Kollisch, M., Thuren, T., Virtanen, J. A., & Kinnunen, P. K. (1987). Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry, 22(4), 421-426.
42. Glass, M., Draunow, M., & Faull, R. L. (2000). The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97(3), 505-519.
43. Glass, M., Faull, R. L., & Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntinton's disease. Neuroscience, 56(3), 523-527.
44. Glazer, W. M., & Moore, D. C. (1993). Psychiatric treatment programs: the continuous service model. Employment Benefits Journal, 18(2), 30-36.
45. Glazer, W. M., Moore, D. C., Schooler, N. R., Brenner, L. M., & Morgenstern, H. (1984). Tardive dyskinesia. A discontinuation study. Archives of General Psychiatry, 41(6), 623-627.
46. Glen, A. I., Glen, E. M., Horrobin, D. F., Vaddadi, K. S., Spellman, M., Morse-Fisher, N., et al. (1994). A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophrenia Research, 12(1), 53-61.
47. Gorriti, M. A., Rodriguez de Fonseca, F., Navarro, M., & Palomo, T. (1999). Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. European Journal of Pharmacology, 365(2-3), 133-142.
48. Grimm, J. W., Chapman, M. A., Zahm, D. S., & See, R. E. (2001). Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse, 39(1), 51-57.
49. Guy, W., Ban, T. A., & Wilson, W. H. (1986). The prevalence of abnormal involuntary movements among chronic schizophrenics. International Clinical Psychopharmacology, 1(2), 134-144.
50. Halliwell, B., & Gutteridge, J. M. (1985). The importance of free radicals and catalytic meta ions in human diseases. Molecular Aspects of Medicine, 8(2), 89-193.
51. Hensley, R., & Floyd, R. A. (2002). Reactive oxygen species and protein oxidation in aging: A look back, a look ahead. Archives of Biochemistry and Biophysics, 397(2), 377-383.
52. Henzl, M. R. (2004). Perspectives and clinical significance of eicosanoids in immunology, endocrinology and metabolic regulation. In P. Curtis-Prior (Ed.), The Eicosanoids (pp. 227-236). UK: Wiley & Sons.
53. Herkenham, M., Lynn, A. B., de Costa, B. R., & Richfield, E. K. (1991). Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research, 547, 267-274.
54. Hibblen, J. (1999). Long-chain polyunsaturated fatty acids in depression and related conditions. In M. Peet, I. Glen & D. F. Horrobin (Eds.), Phospholipid Spectrum Disorder in Psychiatry (pp. 195-210). Carnforth: Marius Press.
55. Hibbeln, J. R., Makino, K. K., Martin, C. E., Dickerson, F., Boronow, J., & Fenton, W. S. (2003). Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biological Psychiatry, 53, 431-441.
56. Holt, D. J., Herman, M. M., Hyde, T. M., Kleinman, J. E., Sinton, C. M., German, D. C., et al. (1999). Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience, 94(1), 21-31.
57. Hori, H., Ohmori, O., Shinkai, T., Kojima, H., Okano, C., Suzuki, T., et al. (2000). Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia. Neuropsychopharmacology, 23(2), 170-177.
58. Horrobin, D. F. (1991). Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry, 30(8), 795-805.
59. Horrobin, D. F. (1998). The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research, 30(3), 193-208.
60. Horrobin, D. F. (1999a). The effects of antipsychotic drugs on membrane phospholipids: A possible novel mechanism of action of clozapine. In Malcolm Peet, I.G.a.D.F.H. (Ed.), Phospholipid Spectrum Disorder in Psychiatry (pp. 113-117). Lancashire, UK: Marius Press.
61. Horrobin, D. F. (1999b). The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopment concept of schizophrenia. In Malcolm Peet, I.G.a.D.F.H. (Ed.), Phospholipid Spectrum Disorder in Psychiatry (pp. 3-20). Lancashire, UK: Marius Press.
62. Horrobin, D. F. (2003). Omega-3 fatty acid for schizophrenia. American Journal of Psychiatry, 160(1), 188-189.
63. Horrobin, D. F., Glen, A. I., & Vaddadi, K. S. (1994). The membrane hypothesis of schizophrenia. Schizophrenia Research, 13(3), 195-207.
64. Inada, T., Senoo, H., Iijima, Y., Yamauchi, T., & Yagi, G. (2003). Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatric Genetics, 13(3), 163-168.
65. Jeding, I., Evans, P. J., Akanmu, D., Dexter, D., Spencer, J. D., Aruoma, O. I., Jenner, P., & Halliwell, B. (1995). Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochemical Pharmacology, 49, 359-365.
66. Jenkins, A. P., & Thompson, R. P. (1993). Does the fatty acid profile of dietary fat influence its trophic effect on the small intestinal mucosa. Gut, 34(3), 358-264.
67. Jeste, D. V., Caligiuri, M. P., Paulsen, J. S., Heaton, R. K., Lacro, J. P., Harris, M. J., et al. (1995). Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52(9), 756-765.
68. Jeste, D. V., Karson, C. N., Iager, A. C., Bigelow, L. B., & Wyatt, R. J. (1984). Association of abnormal involuntary movements and negative symptoms. Psychopharmacology Bulletin, 20(3), 380-381.
69. Jeste, D. V., Lohr, J. B., & Manley, M. (1992). Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with flupheazine in rats. Psychopharmacology (Berl), 106(2), 154-160.
70. Jeste, D. V., Lohr, J. B., Clark, K., & Wyatt, R. J. (1988). Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology, 8(4), 38-48.
71. Kaiya, H. (1984). Prostaglandin E1 treatment of schizophrenia. Biological Psychiatry, 19, 457-462.
72. Kane, J. M., Woerner, M., & Lieberman, J. (1988). Tardive dyskinesia: Prevalence, incidence and risk factors. Journal of Clinical Psychopharmacology, 39(4), 473-481.
73. Kapur, S., & Seeman, P. (2001). Does fast association from the dopamine D2 receptor explain the action of atypical antipsychotcs? A new hypothesis. American Journal of Psychiatry, 158(3), 360-369.
74. Kassis, V., & Sondergaard, J. (1983). Prostaglandin E1 in normal human skin: Mthodological evaluation, topographical distribution and data related to sex and age. Archives for Dermatological Research, 275(1), 9-13.
75. Katayama, K., Ueda, N., Kurahashi, Y., Suzuki, H., Yamamoto, S., & Kato, I. (1997). Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochimica et Biophysica Acta, 1347(2-3), 212-218.
76. Khan, M. M., Parikh, V. V., & Mahadik, S. P. (2003). Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. Journal of Neurochemistry, 86(5), 1089-1100.
77. Klawans Jr., H. L., & Rubovits, R. (1972). An experimental model of tardive dyskinesia. Journal of Neural Transmmission, 33(3), 235-246.
78. Kropp, S., Kern, V., Lange, K., Degner, D., Hajak, G., Kornhuber, J., et al. (2005). Oxidative stress during treatment with first- and second-generation antipsychotics. The Journal of Neuropsychiatry and Clinical Neurosciences, 17(2), 227-231.
79. Lai, I. C., Wang, Y. C., Lin, C. C., Bai, Y. M., Liao, D. L., Yu, S. C., et al. (2005). Negative association between Catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. Journal of Neural Transmission, 112(8), 1107-1113.
80. Lastres-Becker, I., Hansen, H. H., Berrendero, F., De Miguel, R., Perez-Rosado, A., Manzanares, J., et al. (2002). Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse, 44(1), 23-35.
81. Lees, A. J. (1985). Parkinson's disease and dementia. Lancet, 1(8419), 43-44.
82. Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991). The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503-510.
83. Lindenmayer, J. P., Kay, S. R., & Opler, L. (1984). Positive and negative subtypes in acute schizophrenia. Comprehensive Psychiatry, 25(4), 455-464.
84. Liou, Y. J., Wang, Y. C., Bai, Y. M., Lin, C. C., Yu, S. C., Liao, D. L., et al. (2004). Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 49(4), 167-173.
85. Lohr, J. B., Cadet, J. L., Lohr, M. A., Larson, L., Wasli, E., Wade, L., Hylton, R., Vidoni, C., Jeste, D. V., & Wyatt, R. J. (1988). Vitamin E in the treatment of tardive dyskinesia: The possible involvement of free radical mechanisms. Schizophrenia Bulletin, 14, 291-296.
86. Lohr, J. B. (1991). Oxygen radicals and neuropsychiatric illness. Some speculations. Archives of General Psychiatry, 48(12), 1097-1106.
87. Lohr, J. B., & Browning, J. A. (1995). Free radical involvement in neuropsychiatric illnesses. Psychopharmacology Bulletin, 31(1), 159-165.
88. Lohr, J. B., Kuczenski, R., & Niculescu, A. B. (2003). Oxidative mechanisms and tardive dyskinesia. CNS Drugs, 17(1), 47-62.
89. Lucey, J. V., & Dinan, T. G. (1992). Oroacial dyskinesia and the alcohol dependence syndrome. Psychological Medicine, 22(1), 79-83.
90. Mahadik, S. P., & Evans, D. R. (2003). Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. The Psychiatric Clinics of North America, 26(1), 85-102.
91. Mahadik, S. P., & Scheffer, R. E. (1996). Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrines and Essential Fatty Acids, 55(1-2), 45-54.
92. Mahadik, S. P., Laev, H., Korenovsky, A., & Karpiak, S. E. (1988). Haloperidol alters rat cholinergic system: Enzymatic and morphological analyses. Biological Psychiatry, 24(2), 199-217.
93. Mahadik, S. P., Mukherjee, S., Correnti, E. E., Kelkar, H. S., Wakade, C. G., Costa, R. M., et al. (1994). Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophrenia Research, 13(3), 239-247.
94. Mailleux, P., & Vanderhaeghen, J. J. (1992a). Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radio-autography and in situ hybridization histochemistry. Neuroscience, 48(3), 655-668.
95. Mailleux, P., & Vanderhaeghen, J. J. (1992b). Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum. Neuroscience Letter, 147(2), 179-181.
96. Margolese, H. C., Chouinard, G., Kolivakis, T. T., Beauclair, L., & Miller, R. (2005a). Tardive dyskinesia in the era of typical and atypical antipsychotics, Part 1: Pathophysiology and mechanism of induction. Canadian Journal of Psychiatry, 50(9), 541-547.
97. Margolese, H. C., Chouinard, G., Kolivakis, T. T., Beauclair, L., Miller, R., & Annable, L. (2005b). Tardive dyskinesia in the era of typical and atypical antipsychotics, Part 2: Incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry, 50(11), 703-714.
98. Matsumoto, C., Shinkai, T., Hori, H., Ohmori, O., & Nakamura, J. (2004). Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry and Research, 127(1-2), 1-7.
99. McGrath, J. J.,, & Soares, K. V. (2000a). Benzodiazepines for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews, (2), Art. No: CD000205.
100. McGrath, J. J., & Soares, K. V. (2000b). Cholinergic medication for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews, (2), Art. No: CD000207.
101. McGrath, J. J., & Soares, K. V. (2000c). Miscellaneuous treatments for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews, (2), Art. No: CD000208.
102. McGrath, J. J., & Soares, K. V. (2000d). Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. The Cochrane Database of Systematic Reviews, (2), Art. No: CD000459.
103. Mellor, J. E., Laugharne, J. D., & Peet, M. (1995). Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophrenia Research, 18(1), 85-86.
104. Miller, D. D. (2005). Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophrenia. Research, 80(1), 33-43.
105. Miller, R., & Chouinard, G. (1993). Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry, 34(10), 713-738.
106. Morgenstern, H., & Glazer, W. M. (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry, 50(9), 723-733.
107. Mukherjee, S., Wisniewski, A., Bilder, R., & Sackeim, H. A. (1985). Possible association between tardive dyskinesia and altered carbohydrate metabolism. Archive of General Psychiatry, 42, 205.
108. Naidu, P. S., Singh, A., & Kulkarni, S. K. (2003b). Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Psychopharmacology (Berl), 167(4), 418-423.
109. Naidu, P. S., Singh, A., Kaur, P., Sandhir, R., & Kulkarni, S. K. (2003a). Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacology Biochemistry and Behaviour, 74(3), 641-648.
110. Newcomer, J. W. (2004). Metabolic risk during antipsychotic treatment. Clinical Therapeutics, 26(12), 1936-1946.
111. Nikoloff, D., Shim, J. C., Fairchild, M., Patten, N., Fijal, B. A., Koch, W. H., et al. (2002). Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. The Pharmacogenomics Journal, 2(6), 400-407.
112. Nilsson, A., Horrobin, D. F., Rosengren, A., Waller, L., Adlerberth, A., & Wilhelmsen, L. (1996). Essential fatty acids and abnormal involuntary movements in the general male population: A study of men born in 1933. Prostaglandins, Leukotrienes and Essential Fatty Acids, 55, 83-87.
113. Nohria, V., & Vaddadi, K. S. (1982). Tardive dyskinesia and essential fatty acids: An animal model study. In D. F. Horrobin (Ed.), Clinical uses of essential fatty acids (pp. 199-204). Montreal: Eden Press.
114. Olivera, A. A., Kiefer, M. W., & Manley, N. K. (1990). Tardive dyskinesia in psychiatric patients with substance use disorders. American Journal of Drug and Alcohol Abuse, 16, 57-66.
115. Opler, L. A., Kay, S. R., Rosado, V., & Lindenmayer, J. P. (1984). Positive and negative symptoms in chronic schizophrenic patients. The Journal of Nervous and Mental Disease, 172(6), 317-325.
116. Pae, C. U., Yu, H. S., Kim, J. J., Lee, C. U., Lee, S. J., Jun, T. Y., et al. (2004). Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. International Journal of Neuropsychpharmacology, 7(4), 495-500.
117. Patsopoulos, N. A., Nitzani, E. E., Zintzaras, E., & Ioannidis, J. P. (2005). Cyp2D6 polymorphism and the risk of tardive dyskinesia in schizophrenia: A meta-analyses. Pharmacogenetics and Genomics, 15(3), 151-158.
118. Paulsen, J. S., Caligiuri, M. P., Palmer, B., McAdams, L. A., & Jeste, D. V. (1996). Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study. Psychopharmacology (Berl), 123(4), 307-314.
119. Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research, 49(3), 243-251.
120. Peet, M., Laugharne, J. D., Mellor, J., & Ramchand, C. N. (1996). Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins, Leukorienes and Essential Fatty Acids, 55(1-2), 71-75.
121. Peet, M., Laugharne, J. D., Rangarajan, N., Horrobin, D. F., & Reynolds, G. (1995). Depleted red cell membrane essential fatty acids in drug treated schizophrenic patients. Journal of Psychiatric Research, 29, 227-232.
122. Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74(2), 129-180.
123. Piomelli, D., Guiffrida, A., Calignano, A., & Rodriguez de Fonseca, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences, 21(6), 218-224.
124. Polydoro, M., Schroder, N., Lima, M. N., Caldana, F., Laranja, D. C., Bromberg, E., et al. (2004). Haloperidol- and clozapine-induced oxidative stress in rat brain. Pharmacology, Biochemistry and Behaviour, 78(4), 751-756.
125. Pryor, G. T., Larsen, F. F., Husain, S., & Braude, M. C. (1978). Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacology, Biochemistry and Behaviour, 8(3), 295-318.
126. Puri, B. K., & Richardson, A. J. (1998). Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Archives of General Psychiatry, 55(2), 188-189.
127. Puri, B. K., Bydder, G. M., Counsell, S. J., Corridan, B. J., Richardson, A. J., Hajnal, J. V., et al. (2002). MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. NeuroReport, 13(1), 123-126.
128. Puri, B. K., Leavitt, B. R., Hayden, M. R., Ross, C. A., Rosenblatt, A., Greenamyre, J. T., et al. (2005). Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology, 65(2), 286-292.
129. Reynolds, G. P., Templeman, L. A., & Zhang, Z. J. (2005). The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuropsychopharmacological and Biological Psychiatry, 29, 1021-1028.
130. Richardson, M. A., Pass, R., Bregman, Z., & Craig, T. J. (1985). Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacology Bulletin, 21(1), 130-135.
131. Richfield, E. K., & Herkenham, M. (1994). Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Annals of Neurology, 36, 577-584.
132. Ross, D. E., Thomas, M., Booth, M., & Weinborn, M. (2005). Rate of tardive dyskinesia in hospitalized patients. American Journal of Psychiatry, 162, 816.
133. Sarsilmaz, M., Songur, A., Ozyurt, H., Kus, I., Ozen, O. A., Ozyurt, B., et al. (2003). Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 69(4), 253-259.
134. See, R. E., & Lynch, A. M. (1996). Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. European Journal of Pharmacology, 308(3), 279-282.
135. Segman, R. H., Heresco-Levy, U., Yakir, A., Goltser, T., Strous, R., Greenberg, D. A., et al. (2002). D3 receptor gene polymorphism on abnormal involuntary movements in chronic schizophrenia. Biological Psychiatry, 51(3), 261-263.
136. Shamir, E., Barak, Y., Shalman, I., Laudon, M., Zisapel, N., Tarrasch, R., et al. (2001). Melatonin treatment for tardive dyskinesia: A double-blind placebo controlled crossover study. Archives of General Psychiatry, 58(11), 1049-1052.
137. Silvestri, S., Seeman, M. V., Negrete, J. C., Houle, S., Shammi, C. M., Remington, G. J., et al. (2000). Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl), 152(2), 174-180.
138. Singh, A., Naidu, P. S., & Kulkarni, S. K. (2003). Possible annoxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. European Journal of Pharmacology, 477(2), 87-94.
139. Soares, K. V., & McGrath, J. J. (2001). Vitamine E for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews, (Issue 4), Art. No: CD000209.
140. Soares, K. V., McGrath, J. J., & Deeks, J. J. (2001). Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews, (Issue 2), Art. No: CD000203.
141. Tan, E. C., Chong, S. A., Mahendran, R., Dong, F., & Tan, C. H. (2001). Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biological Psychiatry, 50(2), 144-147.
142. Tiwari, A. K., Deshpande, S. N., Rao, A. R., Bhatia, T., Lerer, B., Nimgaonkar, V. L., et al. (2005). Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene. Schizophrenia Research, 75(1), 21-26.
143. Tsai, G., Goff, D. C., Chang, R. W., Flood, J., Baer, L., & Coyle, J. T. (1998). Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. The America Journal of Psychiatry, 155(9), 1207-1213.
144. Tsay, H. J., Wang, P., Wang, S. L., & Ku, H. H. (2000). Age-associated changes of superoxide dismutase and catalase activities in the rat brain. Journal of Biomedical Science, 7(6), 466-474.
145. Vaddadi, K. S. (1984). Essential fatty acids and neuroleptic drug induced tardive dyskinesia: Preliminary clinical observations. IRCS Medical Science, 12, 678-679.
146. Vaddadi, K. S., Courtney, P., Gilleard, C. J., Manku, M. S., & Horrobin, D. F. (1989). A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research, 27(3), 313-323.
147. Vaddadi, K. S., Gilleard, C. J., Soosai, E., Polonowita, A. K., Gibson, R. A., & Burrows, G. D. (1996). Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophrenia Research, 20(3), 287-294.
148. Vaddadi, K. S., Soosai, E., Chiu, E., & Dindjan, P. A. (2002). A randomized, placebo-controlled, double-blind study of treatment of Huntington's disease with unsaturated fatty acids. NeuroReport, 13, 29-33.
149. Van Raamsdonk, J. M., Pearson, J., Rogers, D. A., Lu, G., Barakauskas, V. E., Barr, A. M., et al. (2005). Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology, 196(2), 266-272.
150. Vinod, K. Y., & Hungund, B. L. (2005). Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. Life Sciences, 77(14), 1569-1583.
151. Vinod, K. Y., Arango, V., Xie, S., Kassir, S. A., Mann, J. J., Cooper, T. B., et al. (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biological Psychiatry, 57(5), 480-486.
152. Waddington, J. L. (1989). Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: The enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. International Reviews in Neurobiology, 31, 297-353.
153. Waddington, J. L. (1995). Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Advances in Neurology, 65, 211-229.
154. Waddington, J. L., & Youssef, H. A. (1986). Late onset involuntary movements in chronic schizophrenia: Relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms. British Journal of Psychiatry, 149, 616-620.
155. Wang, L., Liu, J., Harvey-White, J., Zimmer, A., & Kunos, G. (2003).
156. Watanabe, S., & Doshi, T. (2003). n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins, Leukotrienes and Essential Fatty Acids, 69(1), 51-59.
157. Wickens, A. P. (2001). Ageing and the free radical theory. Respiration Physiology, 128(3), 379-391.
158. Wolkin, A., Jordan, B., Peselow, E., Rubinstein, M., & Rotrosen, J. (1986). Essential fatty acids supplementation in tardive dyskinesia. The American Journal of Psychiatry, 143(7), 912-914.
159. Wonodi, I., Adami, H. M., Cassady, S. L., Sherr, J. D., Avila, M. T., & Thaker, G. K. (2004). Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. Journal of Clinical Psychopharmacology, 24(6), 592-598.
160. Yao, J. K., van Kammen, D. P., & Welker, J. A. (1994). Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research, 13(3), 217-226.
161. Youssef, H. A., & Waddington, J. L. (1987). Morbidity and mortality in tardive dyskinesia: Associations in chronic schizophrenia. Acta Psychiatrica Scandinavica, 75(1), 74-77.
162. Zhang, X. Y., Zhou, D. F., Cao, L. Y., Xu, C. Q., Chen da, C., & Wu, G. Y. (2004). The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: A double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology, 24(1), 83-86.
163. Zhang, Z. J., Zhang, X. B., Hou, G., Yao, H., & Reynolds, G. P. (2003). Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatric Genetics, 13(3), 187-192.